Form 4: CRL Executive Acquires Shares via RSU Grant

Charles River Laboratories' CSVP, CAO, and Interim CFO, Michael G. Knell, acquired 2,926 shares of common stock through a restricted stock unit grant.

Summary

• Michael G. Knell, CSVP, CAO, and Interim CFO of Charles River Laboratories International, Inc. (CRL), acquired 2,926 shares of common stock.
• The transaction occurred on November 6, 2025, at a price of $170.88 per share.
• Following this acquisition, Knell beneficially owns 13,460 shares of common stock directly.
• The acquired shares are unvested restricted stock units, with 50% vesting on November 6, 2026, and the remaining 50% vesting on November 6, 2027.

Sentiment

Score: 7

Explanation: The acquisition of shares by an executive, particularly through restricted stock units, generally indicates management's confidence in the company's long-term prospects and aligns executive incentives with shareholder interests. This is a positive signal, though it's a routine compensation event rather than a major strategic announcement.

Positives

• An executive acquiring shares, particularly through restricted stock units, aligns management's long-term interests with those of shareholders.
• The vesting schedule provides a retention incentive for a key executive.

Future Outlook

The vesting schedule for the restricted stock units indicates a long-term retention and incentive plan for the executive, aligning their interests with future company performance over the next two years.

Industry Context

Insider purchases, especially of restricted stock units, are common mechanisms for executive compensation and retention across various industries, including the life sciences and pharmaceutical services sector where Charles River Laboratories operates. This transaction reflects a standard practice for incentivizing key personnel.

Comparison to Industry Standards

• This type of RSU grant and vesting schedule is a standard practice for executive compensation in publicly traded companies, comparable to similar plans at peers in the contract research organization (CRO) and life sciences tools sectors.
• The grant price of $170.88 per share reflects the market value at the time of the grant, consistent with typical RSU awards.

Stakeholder Impact

• Shareholders: Executive share acquisition can be seen as a positive signal of confidence in the company's future performance.
• Employees: Standard executive compensation practices can influence morale and retention within the organization.

Next Steps

• 50% of the acquired restricted stock units will vest on November 6, 2026.
• The remaining 50% of the acquired restricted stock units will vest on November 6, 2027.

Key Dates

Recommendation

The filing details a routine executive compensation event involving the acquisition of restricted stock units. While insider buying can be a positive signal of management confidence, this specific transaction, being an RSU grant with a vesting schedule, is a standard part of executive incentive plans rather than a discretionary open-market purchase. It reinforces alignment with long-term shareholder interests but does not present new information warranting a change in investment thesis.

Keywords

Charles River Laboratories, CRL, Insider Transaction, Form 4, Stock Acquisition, Restricted Stock Units, Executive Compensation, Michael G. Knell